Programma di Terapia Per Pazienti Affetti da Linfoma Diffuso a Grandi Cellule B CD20 Positive
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Failure-free survival
Three years
Umberto Vitolo, MD
Principal Investigator
S.C. Ematologia II - OSP.S. GIOV.BATTISTA MOLINETTE - TORINO (TO) -
Italy: The Italian Medicines Agency
GIMURELL-DLBCL
NCT00556127
June 2002
September 2006
Name | Location |
---|